Septerna (SEPN) Competitors

In the previous week, Septerna had 3 more articles in the media than Cogent Biosciences. MarketBeat recorded 5 mentions for Septerna and 2 mentions for Cogent Biosciences. Septerna's average media sentiment score of 0.40 beat Cogent Biosciences' score of 0.38 indicating that Septerna is being referred to more favorably in the news media.

Septerna has higher revenue and earnings than Cogent Biosciences. Septerna is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Cogent Biosciences presently has a consensus price target of $43.73, indicating a potential upside of 15.53%. Septerna has a consensus price target of $45.78, indicating a potential upside of 33.27%. Given Septerna's stronger consensus rating and higher probable upside, analysts plainly believe Septerna is more favorable than Cogent Biosciences.

Cogent Biosciences has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Cogent Biosciences' return on equity.

Cogent Biosciences has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Septerna has a beta of 2.39, suggesting that its share price is 139% more volatile than the broader market.

Septerna has a beta of 2.39, meaning that its stock price is 139% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

Scholar Rock has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Scholar Rock's return on equity.

91.1% of Scholar Rock shares are owned by institutional investors. 5.8% of Septerna shares are owned by insiders. Comparatively, 13.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Septerna has higher revenue and earnings than Scholar Rock. Septerna is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Septerna presently has a consensus price target of $45.78, indicating a potential upside of 33.27%. Scholar Rock has a consensus price target of $56.00, indicating a potential upside of 3.12%. Given Septerna's higher probable upside, equities analysts plainly believe Septerna is more favorable than Scholar Rock.

In the previous week, Septerna had 1 more articles in the media than Scholar Rock. MarketBeat recorded 5 mentions for Septerna and 4 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.99 beat Septerna's score of 0.40 indicating that Scholar Rock is being referred to more favorably in the news media.

Belite Bio has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Belite Bio's return on equity.

Belite Bio currently has a consensus target price of $203.00, suggesting a potential upside of 35.22%. Septerna has a consensus target price of $45.78, suggesting a potential upside of 33.27%. Given Belite Bio's higher probable upside, research analysts clearly believe Belite Bio is more favorable than Septerna.

Septerna has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Septerna, indicating that it is currently the more affordable of the two stocks.

0.5% of Belite Bio shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 5.8% of Septerna shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Belite Bio has a beta of -1.24, meaning that its stock price is 224% less volatile than the broader market. Comparatively, Septerna has a beta of 2.39, meaning that its stock price is 139% more volatile than the broader market.

In the previous week, Septerna had 3 more articles in the media than Belite Bio. MarketBeat recorded 5 mentions for Septerna and 2 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.57 beat Septerna's score of 0.40 indicating that Belite Bio is being referred to more favorably in the media.

Septerna has higher revenue and earnings than CG Oncology. Septerna is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

In the previous week, CG Oncology had 1 more articles in the media than Septerna. MarketBeat recorded 6 mentions for CG Oncology and 5 mentions for Septerna. Septerna's average media sentiment score of 0.40 beat CG Oncology's score of 0.07 indicating that Septerna is being referred to more favorably in the media.

CG Oncology has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat CG Oncology's return on equity.

Septerna has a beta of 2.39, suggesting that its share price is 139% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Septerna currently has a consensus target price of $45.78, suggesting a potential upside of 33.27%. CG Oncology has a consensus target price of $81.73, suggesting a potential upside of 14.11%. Given Septerna's stronger consensus rating and higher possible upside, analysts clearly believe Septerna is more favorable than CG Oncology.

26.6% of CG Oncology shares are owned by institutional investors. 5.8% of Septerna shares are owned by company insiders. Comparatively, 4.8% of CG Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.